A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 2

Conditions studied: Non Small Cell Lung Cancer

In brief

This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).

Key facts

Study ID

NCT01031225

Run by

Synta Pharmaceuticals Corp.

People needed

113

Starts

2009-11-01

Expected to finish

2014-02-01

Last updated by the study team

2014-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression
• Availability of tissue for analysis
• ECOG Performance Status 0 or 1
• Adequate organ function as defined in the protocol.
• Must be at least 18 years old and able and willing to sign a written informed consent document

You may not qualify if…

• Poor venous access requiring an indwelling catheter for study drug administration
• Women who are pregnant or lactating
• Ventricular ejection fraction < or = to 55% at baseline
• Any uncontrolled intercurrent illness

Where it is running

• Arizona Cancer Center; University of Arizona — Tucson, Arizona, United States
• Genesis Cancer Center — Hot Springs, Arkansas, United States
• City of Hope Medical Center — Duarte, California, United States
• UCLA Health System — Santa Monica, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• Emory University- Winship Cancer Institute — Atlanta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Nevada Cancer Institute — Las Vegas, Nevada, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• University of North Carolina, Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States
• Piedmont Hematology Oncology Associates — Winston-Salem, North Carolina, United States
• Oregon Health and Science University — Portland, Oregon, United States
• Penn State Hershey Cancer Institute — Hershey, Pennsylvania, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• Swedish Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.